Name: treatment of asthma: the long-acting beta-2-agonists (en Inglés)
Price: 638855.00 COP
Availability: InStock
Author: Kummer, Friedrich
ISBN: 9783211831243

portada treatment of asthma: the long-acting beta-2-agonists (en Inglés)

Formato

Libro Físico

Ilustrado por

Friedrich Kummer

Editorial

Springer

Autor

Kummer, Friedrich

Año

1998

Idioma

Inglés

N° páginas

186

Encuadernación

Tapa Blanda

Dimensiones

21.6 x 14.0 x 1.1 cm

Peso

0.24 kg.

ISBN

321183124x

ISBN13

9783211831243

Categorías

Medicina clínica e interna
Farmacología
Farmacia y prescripción

treatment of asthma: the long-acting beta-2-agonists (en Inglés)

Friedrich Kummer (Ilustrado por) · Springer · Tapa Blanda

Libro Nuevo

$ 638.855

$ 982.854

Ahorras: $ 343.999

35% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Lunes 08 de Julio y el Lunes 22 de Julio.

Lo recibirás en cualquier lugar de Colombia entre 1 y 5 días hábiles luego del envío.

Reseña del libro "treatment of asthma: the long-acting beta-2-agonists (en Inglés)"

The traditional Vienna Asthma Forum was held in early June 1996 and th was the 6 in a biennial mode within 10 years. This time it was dedicated to the long-acting beta-2-agonists, which were registered (or just about to be) in most European countries. The introduction of this therapeutic principle into routine praxis of asthma therapy was so successful that a closer view on the subject from a scientific point was warranted. Salmeterol, shortly afterwards formo- terol are the drugs available for the inhalative route, while bambuterol serves as an oral agent. The scientists particularly involved in the design and pharma- cokinetics of these drugs were invited, and we were lucky that Malcolm Johnson (Glaxo), Leif Svensson (Astra) and Gary Anderson (Ciba- Geigy) delivered fascinating contributions. However, drug therapy of this kind can only be effective if based on a thorough understanding of the molecular biology of cells and receptors, which was superbly covered by Sheila Collins (Durham) and Ian M. Adcock (London). The pediatric indications for beta-2-agonists were commented by Manfred G6tz (Vienna), and a large spectrum of clinical studies, reported by G. Boyd (Glasgow), A.P. Greening (Edinburgh), M.